GENFIT Signs Research Partnership with EVerZom to Advance Exosome-Based Regenerative Medicine Technology in ACLF.

GENFIT has partnered with EVerZom to advance a regenerative medicine technology based on exosomes for the treatment of Acute-on-Chronic Liver Failure (ACLF). The experimental drug candidate EViv, developed by EVerZom using its proprietary exosome platform, represents a novel approach in regenerative therapies. GENFIT will lead the preclinical evaluation of EViv, while EVerZom will provide its unique expertise in exosomes and bioproduction platform. In case of positive in vivo proof-of-concept results, GENFIT has an exclusive option to license EViv for further clinical development.